#1
|
|||
|
|||
Îçîíîòåðàïèÿ è ÓÔÎ êðîâè ïðè îíêîçàáîëåâàíèÿõ!
Äîáðîãî âñåì äíÿ!
Åñòü ëè ó êîãî-íèáóäü ññûëêè íà ñòàòüè î ïðèìåíåíèè îçîíîòåðàïèè äëÿ ñíèæåíèÿ òîêñè÷åñêîãî âîçäåéñòâèÿ õèìèîòåðàïèè? Íàñêîëüêî îïðàâäàíî ïðèìåíåíèå îçîíîòåðàïèè è ÓÔÎ êðîâè ó îíêî áîëüíûõ? Íå ñòèìóëèðóåò ëè ýòî ìåòàáîëèçì,à çàîäíî è ðîñò îïóõîëè? Ïîæàëóéñòà ïî âîçìîæíîñòè ïèøèòå ìíå íà linado(at)rambler.ru Ñ óâàæåíèåì! Ëþáîâü |
#2
|
||||
|
||||
À ýòî Âàì çà÷åì?
|
#3
|
||||
|
||||
Îçîíîòåðàïèÿ ïðè ðàêå?
-------------------------------------------------------------------------------- [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "The most touted agents are hydrogen peroxide, germanium sesquioxide, and OZONE. Although these compounds have been the subject of legitimate research, there is LITTLE OR NO EVIDENCE THAT THEY ARE EFFECTIVE for the treatment of any serious disease, and EACH HAS DEMONSTRATED POTENTIAL FOR HARM. " A primer of complementary and alternative medicine commonly used by patients Ernst E.The Medical Journal of Australia 15 Jan2001; 174: 88–92.“ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Abstract: Complementary and alternative medicine (CAM) is frequently used by cancer patients,and many oncologists have limited knowledge of CAM. This article provides a brief, evidence-based introduction to several CAM treatments relevant in the context of cancer. “Alternative”diets, chiropractic, coffee enemas, OZONE THERAPY, and shark cartilage seem to have little to offer cancer patients. The evidence for or against homoeopathy and spiritual healing is at present inconclusive. Acupuncture, aromatherapy, and meditation may be useful for nausea/vomiting, for mild relaxation, and for pain/anxiety, respectively. Herbal treatments offer no reasonable prospect of a cure (mistletoe), but could be useful as palliative treatments (eg, for depression [StJohn’s wort] or anxiety [kava]). Our knowledge regarding the potential benefit and harm of CAMis insufficient. Àáñòðàêò: Îíêîëîãè÷åñêèå ïàöèåíòû äîâîëüíî ÷àñòî ïðèáåãàþò ê ïîìîùè àëüòåðíàòèâíîé èëè êîìïëåìåíòàðíîé ìåäèöèíû, îäíàêî îíêîëîãè ÷àñòî íå èìåþò îá ýòîì íåîáõîäèìûõ çíàíèé.  ýòîé ñòàòüå ïðåäëàãàåòñÿ êðàòêîå evidence-based çíàêîìñòâî ñ íåêîòîðûìè ìåòîäàìè àëüòåðíàòèâíîãî öåëèòåëüñòâà îíêîëîãè÷åñêèõ çàáîëåâàíèé. Ïîêàçàíî, ÷òî "àëüòåðíàòèâíûå" äèåòû, õèðîïðàêòèêà. êîôåéíûå êëèçìû, ÎÇÎÍÎÒÅÐÀÏÈß, àêóëüè õðÿùè íå îêàçûâàþò íèêàêîãî ïîëîæèòåëüíîãî äåéñòâèÿ ïðè îíêîëîãè÷åñêèõ çàáîëåâàíèÿõ. Íåò äàííûí çà èëè ïðîòèâ ãîìåîïàòèè è ñïèðèòóàëüíîãî öåëèòåëüñòâà. Àêóïóíêòóðà. àðîìàòîòåðàïèÿ è ìåäèòàöèÿ èíîãäà ìîãóò áûòü ýôôåêòèâíû ïðè òîøíîòå è ðâîòå, äëÿ ðåëàêñàöèè, êóïèðîâàíèÿ áîëè è òðåâîãè, ñîîòâåòñòâåííî. Ëå÷åíèå òðàâàìè íå îêàçûâàåò íèêàêîãî âëèÿíèÿ íà îïóõîëåâûé ïðîöåññ, íî ìîæåò áûòü èñïîëüçîâàíî äëÿ ïàëëèàòèâíîãî ëå÷åíèÿ (íàïðèìåð, ïðè äåïðåññèè è òðåâîæíîñòè).  öåëîì íàøè çíàíèÿ î ïîòåíöèàëüíîì âðåäå èëè ïîëüçå àëüòåðíàòèâíûõ ìåòîäîâ ëå÷åíèÿ íåäîñòàòî÷íû. "If you hear that an "alternative" method has produced "miraculous" recoveries from cancer, you should be skeptical. There are at least five reasons why such a report may be erroneous: 1.The patient never had cancer. 2.The cancer was cured or put into remission by proven therapy, but questionable therapy was also used and erroneously credited for the beneficial result. 3.The cancer is progressing but is erroneously represented as slowed or cured. 4.The patient represented as cured may have died as a result of the cancer or been lost to follow-up. 5.The patient had a spontaneous remission (very rare) or slow-growing cancer that was publicized as a cure. " Stephen Barrett, M.D. ÏÅÐÅÂÎÄ "Åñëè Âû óñëûøàëè, ÷òî "àëüòåðíàòèâíûé" ìåòîä âûçûâàë "âîëøåáíûå" èñöåëåíèÿ îíêîëîãè÷åñêèõ çàáîëåâàíèé, îòíîñèòåñü ê ýòîìó ñêåïòè÷åñêè. Ñóùåñòâóåò ïî êðàéíåé ìåðå ïÿòü ïðè÷èí, ïî êîòîðûì ýòè çàÿâëåíèÿ ìîãóò áûòü îøèáî÷íûìè: 1.Ó ïàöèåíòà íèêîãäà íå áûëî ðàêà. 2.Ðàê áûë âûëå÷åí èëè ïåðåâåäåí â ñîñòîÿíèå ðåìèññèè äîêàçàííî ýôôåêòèâíîé òåðàïèåé. Àëüòåðíàòèâíûå ìåòîäû èñïîëüçîâàëèñü îäíîâðåìåííî è îøèáî÷íî âûäàþòñÿ çà "ëå÷åíèå", âûçâàâøåå ðåìèññèþ èëè èçëå÷åíèå. 3.Ðàê â äåéñòâèòåëüíîñòè ïðîãðåññèðóåò, íî îøèáî÷íî ïðåäñòàâëÿåòñÿ ðåãðåññèðóþùèì èëè èçëå÷åííûì. 4.Ïàöèåíò áîëüøå íå íàáëþäàåòñÿ ïî ïîâîäó îíêîëîãè÷åñêîãî çàáîëåâàíèÿ è âûäàåòñÿ çà âûçäîðîâåâøåãî.  äåéñòâèòåëüíîñòè, ïàöèåíò óìåð îò îíêîëîãè÷åñêîãî çàáîëåâàíèÿ. 5.Ïðîèçîøëà ñïîíòàííàÿ ðåìèññèÿ (ðåäêî) èëè ïðîöåññ î÷åíü ìåäëåííûé, è ýòîò ñëó÷àé ïðåäñòàâëÿþò êàê âûçäîðîâëåíèå â ðåçóëüòàòå àëüòåðíàòèâíîãî ëå÷åíèÿ. " Ñòèâåí Áàððåò,M.D. |
#4
|
|||
|
|||
Ñïàñèáî çà ñòàòüè yananshs!! Your translation was very much appreciated. In fact I speak some English so there is no need to translate; I have got my MSc medical degree from a European country. Here is another article I came across.Ïðîñòî èíòåðåñíî óçíàòü, åñòü ëè íà íàñòîÿùåå âðåìÿ îáùàÿ òî÷êà çðåíèÿ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 1990 Experimental Chemotherapy 1990;36:147-154 "In vitro Synergistic Activity of 5-Fluorouracil with Low-Dose Ozone against a Chemoresistant Tumor Cell Line and Fresh Human Tumor Cells" "Our results indicate that ozone in combination with 5-fluorouracil (5-FU) makes a 5-FU resistant cell line susceptible for the combined treatment modality. Furthermore, ozone acts synergistically or at least additive to chemotherapy in different tumor cell suspensions, derived from the breast and the colon." |
#5
|
|||
|
|||
Öèòàòà:
|
#6
|
|||
|
|||
Âîò åùå ñòàòüÿ â çàùèòó îçîíîòåðàïèè.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The continuous treatment with ozone has various points of action in the complex tumoral process, to mention a few: • Ozone is able to regulate the metabolism of oxygen and therefore contributes significantly with the supply of this element to the tissue level, contributes with the metabolization process, fosters production of energy, reestablishing many normal metabolic functions such as reduction of the lactic acidity, activating at the same time the anti-oxidant enzymes. • The oxidative stress that this therapy produces is mortal to the cancerous cells because of its weak anti-oxidant defense system. However normal cells are not affected because they have more effective defense systems against anti-oxidants. Therefore ozone is selective on the cells that attacks. • The modulating activity of the immune system contributes with the reestablishment of the immune system which contributes with the destruction of abnormal cells and contributes with chemotherapy treatments. |
#7
|
||||
|
||||
Ïî÷åìó åùå îäíà? Äà è íå ñòàòüÿ ýòî âîâñå, ýòî ðåêëàìà.
|
|
#8
|
||||
|
||||
Öèòàòà:
À ìíåíèå íàøå Âû, ÿ íàäåþñü, ïîíÿëè. |
#9
|
|||
|
|||
Äà, Âàøå ìíåíèå ÿ ïîíÿëà, ñïàñèáî!
Åñëè ÷åñòíî, òî ñïîðèòü è îáñóæäàòü ìîþ êîìïåòåíòíîñòü íåò íè âðåìåíè, íè æåëàíèÿ. Æàëü, ÷òî íå ïîëó÷èëîñü äèàëîãà. Îçîíîòåðàïèþ êðîâè íàì ïîñîâåòîâàëè â êà÷åñòâå àëüòåðíàòèâíîãî ìåòîäà â îòäåëåíèè õèìèîòåðàïèè, ãäå ìû ïðîõîäèì ëå÷åíèå. Ïîëó÷àåòñÿ, ÷òî ýòî âñå íå ýôôåêòèâíåå êëèçìû ñ êîôå? |
#10
|
||||
|
||||
"Oôèöèàëüíîå ìíåíèå Àìåðèêàíñêîãî Îíêîëîãè÷åñêîãî Îáùåñòâà (American Cancer Society): "Oxygen therapies - íåäîêàçàííîå àëüòåðíàòèâíîå ëå÷åíèå è îáîðóäîâàíèå, ïðåäëàãàåìîå ÷åðåç èíòåðíåò è â êëèíèêàõ Ìåêñèêè, ÑØÀ è Åâðîïû. Äàííûå ìåòîäû âêëþ÷àþò: ëå÷åíèå ïåðåêèñüþ âîäîðîäà ïóò¸ì âíóòðèâåííîãî, ïåðîðàëüíîãî è ðåêòàëüíîãî ââåäåíèÿ èëè ïåðåêèñíûå âàííû; îçîíîâûå êëèçìû è îçîíîâàÿ àóòîãåìîòåðàïèÿ, ïðè êîòîðîé ïðîâîäÿò ýêñòðàêîðïîðàëüíîå îçîíèðîâàíèå êðîâè ñ ïîñëåäóþùåé ðå-èíúåêöèåé, ãèïåðáàðè÷åñêèå êèñëîðîäíûå êàìåðû; îêñèãåíèðîâàííàÿ âîäà, òàáëåòêè è ðàñòâîðû. Ïðè ïåðîðàëüíîì è ðåêòàëüíîì ââåäåíèè îïèñàíû ëåòàëüíûå ñëó÷àè âñëåäñòâèè ãàçîâîé ýìáîëèè, ñåïñèñà è ãàíðåíû, òîãäà êàê âíóòðèâåííîå ââåäåíèå ïðèâîäèëî ê îñòîðîìó ãåìîëèçó è ñìåðòè. Òàêæå îïèñàíû ñëó÷àè çàðàæåíèÿ ãåïàòèòîì Ñ è ÂÈ× ïðè îçîíîâîé àóòîãåìîòåðàïèè. Êèñëîðîäíûå ðàäèêàëû îáðàçóþùèåñÿ ïðè âîçäåéñòâèè îçîíà è ïåðåêèñè ìîãóò îêàçûâàòü ÌÓÒÀÃÅÍÍÎÅ äåéñòâèå. Àìåðèêàíñêîå Îíêîëîãè÷åñêîå Îáùåñòâî ïðèçûâàåò îíêîëîãè÷åñêèõ áîëüíûõ íå îáðàùàòüñÿ çà ëå÷åíèåì ïîñðåäñòâîì ïåðåêèñè è îçîíà. "Oxygen therapies" íå äîëæíû áûòü ðåêîìåíäîâàíû âðà÷àìè."
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#11
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Âû íå ïîëó÷èëè îæèäàåìîãî îòâåòà è îáèæåíû íà íàñ??? Öèòàòà:
|
#12
|
||||
|
||||
Öèòàòà:
|
#13
|
|||
|
|||
Ïîìîùü îíêîáîëüíûì
Ïàïû óæå ãîä êàê íåò, ïðîøëè ÷åðåç âñå, õàìñòâî âðà÷åé, áåçðàçëè÷èå, îò÷àÿíèå, îòñóòñòâèå ïðåïàðàòîâ äëÿ ëå÷åíèÿ è îáåçáîëèâàþùèõ. Ïðîñòèòå, íî âàøå «à âàì ýòî çà÷åì» è îð âðà÷à â îíêîäèñïàíñåðå ÿ íàâðÿä ëè êîãäà-òî çàáóäó. ß ñïîêîéíî ìèìî îíêîäèñïàíñåðà ïðîéòè íå ìîãó, íà÷èíàåò êîëîòèòü. Îòíîøåíèå ìíîãèõ âðà÷åé ìîæíî îïèñàòü ôðàçîé: «îñòàâüòå ìåíÿ â ïîêîå è èäèòå óìðèòå äîìà. Áóäåòå ìó÷àòüñÿ? À ìíå òî, ÷òî. Ìíå è òàê ìàëî ïëàòÿò.» «Ïðàâî ãðàæäàí íà àäåêâàòíîå îáåçáîëèâàíèå» - çëàÿ øóòêà. Ìîæåò âû êîìó-òî è ïîìîãëè, íî ìíå âû ñäåëàëè òîëüêî áîëüíåå. Ïðîñòî õî÷ó ñïðîñèòü, ÷åì ÿ ýòî çàñëóæèëà? Òåì, ÷òî ÿ õîòåëà ñäåëàòü âñå âîçìîæíîå? Ìû íå îòêàçûâàëèñü îò òðàäèöèîííîé õèìèîòåðàïèè. «Âðà÷è íå îáñóæäàþò îçîíîòåðàïèþ». Âû çíàåòå âñå? Ñîìíåâàþñü. Âîò òàê è ÿ. ß ïðîñòî çàäàëà âîïðîñ íà ôîðóìå, ïîòîìó ÷òî íå çíàëà, ñòîèò ëè ñîãëàøàòüñÿ íà îçîíîòåðàïèþ è êîëîòü ïàïó ëèøíèé ðàç. Îí áîÿëñÿ óêîëîâ. Ñêîëüêî áû òû íå çíàë, êîãäà â äîì ïðèõîäèò òàêàÿ áåäà è óìèðàåò ìîëîäîé åùå ÷åëîâåê, ðàñòåðÿííîñòü íå îïèñàòü. ß ïîíèìàþ, ÷òî ÷óæàÿ áåäà ìíîãèì ïî-áàðàáàíó, à õàìñòâî äëÿ ìíîãèõ íàøèõ âðà÷åé – ýòî îáû÷íîå äåëî. Î÷åíü îáèäíî. Áîëüíî. ×åëîâåê ïîãèáàåò. Êàê æå ìîæíî? Îí æå è òàê ìó÷àåòñÿ? À ñ íèì ìó÷àåòñÿ è åãî ñåìüÿ. Ïîñìîòðåëà, êàê ê îíêîáîëüíûì îòíîñÿòñÿ â Èçðàèëå. Áîðþòñÿ äî ïîñëåäíåãî, ïðåïàðàòû áåñïëàòíî, ãðÿçüþ òåáÿ íèêòî íå ïîëèâàåò. ßñíî, ÷òî êîíåö îäèí, íî íåò ýòîãî îò÷àÿíèÿ, áîëè è áåçðàçëè÷èÿ âðà÷åé. Ìîæåòå ìåíÿ çàáàíèòü. Ìíå âñå ðàâíî. Ìîæåò áûòü òî, ÷òî ÿ íàïèñàëà, çàñòàâèò âàñ çàäóìàòüñÿ è ÷òî-òî ïîìåíÿòü.
|
#14
|
|||
|
|||
Ïðî àóòîâàêöèíó ÿ íå çíàþ.
In April 2008, Oncophage® (vitespen; formerly HSPPC-96) was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008. Oncophage is approved only in Russia and Antigenics expects to submit to the European Regulatory Agency before the end of 2008.
|
#15
|
||||
|
||||
Âû çíàåòå, Ëþáîâü, ÑÊÎËÜÊÈÌ áîëüíûì ïîìîã äîêòîð Âàéñìàí? Äà, è ìîèì â òîì ÷èñëå?
Âîïðîñ åãî áûë çàäàí èñêëþ÷èòåëüíî ñ òîé òî÷êè çðåíèÿ, ÷òî îí (îäèí èç íåìíîãèõ â Ðîññèè, êñòàòè) ìîæåò ðåàëüíî ïîìî÷ü áîëüíîìó, è ñïðàøèâàë íå äëÿ òîãî, ÷òîáû Âû âñòàëè â ïîçó è ñðàâíèâàëè åãî òðóä ñ òåìè, êòî âîçìîæíî áûë íåêîððåêòåí. Âîïðîñ áûë çàäàí, ÷òîáû ïîëó÷èòü äîïîëíèòåëüíóþ èíôîðìàöèþ, è âîçìîæíî, äàòü êîíñóëüòàöèþ ïî ðåàëüíûì ìåòîäàì ëå÷åíèÿ. Òàê ÷òî ýòî ÂÀÌ äîëæíî áûòü ñòûäíî, íà ñàìîì äåëå, çà òî, ÷òî Âû ðåøèëè, ÷òî Ìàðê Àçðèåëüåâè÷ ñïðîñèë Âàñ èç-çà ñâîåé ÷åðñòâîñòè. Âû ïî÷èòàéòå äðóãèå òåìû... Ñèñòåìà óæàñíà. ß ñàìà ñèæó áåç íàðêîòèêîâ, à îíêîëîãè÷åñêèõ áîëüíûõ ó ìåíÿ ìíîãî. È ê ñîæàëåíèþ, ìíå íå ó êîãî ñïðîñèòü, êðîìå, êàê ó äîêòîðà Âàéñìàíà. Îí ìíå î÷åíü è î÷åíü ïîìîãàåò. Íåäàâíî óìåðëà ìîÿ ïàöèåíòêà, ñ çàïóùåííûì ðàêîì æåëóäêà, ñ êîòîðîé ìû ñòàëè î÷åíü áëèçêèìè ëþäüìè. È òîëüêî ñîâåò äîêòîð Âàéñìàíà ïîìîã åé äîñòîéíî ïðîæèòü ïîñëåäíèå íåäåëè, õîòÿ áûëî î÷åíü òÿæåëî. Çíàåòå, ïðîñòî áåçîáðàçíî - ñïàñèáî ãîâîðÿò î÷åíü è î÷åíü ðåäêî, à âîò íàïèñàòü ãàäîñòü - ýòî íå çàáóäóò... |